Skip to main content
SpringerLink
Log in

Impact of treatments for osteoporosis on osteoarthritis progression

  • Bone Quality Seminars: Subchondral Bone
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Subchondral bone is involved in the development of osteoarthritis, with an excess in bone resorption at an early stage and increased bone formation thereafter. Experimental and observational studies suggest that acting on bone can change progression of osteoarthritis. Clinical prospective controlled studies failed to confirm this result. Appropriate identification of patients at high risk of developing cartilage deterioration is a key issue for the analysis of impact of treatments for osteoporosis on osteoarthritis progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berry PA, Maciewicz RA, Cicuttini FM, Jones MD, Hellawell CJ, Wluka AE (2010) Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss. J Rheumatol 37:1252–1259

    Article  PubMed  CAS  Google Scholar 

  2. Felson DT, McLaughlin S, Goggins J, LaVallezy MP, Gale ME, Totterman S, Li W, Hill C, Gale D (2003) Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 139:330–336

    PubMed  Google Scholar 

  3. Lo GH, Hunter DJ, Zhang Y et al (2005) Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum 46(12):2814–2821

    Article  Google Scholar 

  4. Muehleman C, Green J, Williams JM, Kuettner KE, Thoner EJ, Sunner DR (2002) The effect of bone remodelling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthr Cartil 10:226–233

    Article  PubMed  CAS  Google Scholar 

  5. Kadri A, Funck-Brentano T, Lin H, Ea HK, Hannouche D, Marty C, Lioté F, Geoffroy V, Cohen-Solal M (2010) Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann Rheum Dis 69:1533–1538

    Article  PubMed  Google Scholar 

  6. Shirai T, Kobayashi M, Nishitani K, Satake T, Kuroki H, Nakagawa Y, Nakamura T (2011) Chrondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 29:1572–1577

    Article  PubMed  CAS  Google Scholar 

  7. Panahifar A, Maksymowych WP, Doschak MR (2012) Potential mechanism of alendeonate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthr Cartil 20:694–702

    Article  PubMed  CAS  Google Scholar 

  8. Hayami T, Zhuo Y, Wesolowski GA, Pickarski M, le Duong T (2012) Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transaction rabbit and murine models of osteoarthritis. Bone 50:1250–1259

    Article  PubMed  CAS  Google Scholar 

  9. Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM, Mooney RA et al (2011) Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med 21:3–10

    Google Scholar 

  10. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BWE, Kritchevsky SB, for the Health Aging and Body Composition Study (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 11:3516–3525

    Article  Google Scholar 

  11. Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT (2008) The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 67:1427–1430

    Article  PubMed  CAS  Google Scholar 

  12. Bruyere O, Delferriere D, Roux C, Wark JD, Spector T, Devogelaer JP et al (2008) Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 67:335–339

    Article  PubMed  CAS  Google Scholar 

  13. Ravaud P, Giraudeau B, Auleley GR, Drape JL, Rousselin B, Paolozzi L, Chastang C, Dougados M (1998) Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis 57:624–629

    Article  PubMed  CAS  Google Scholar 

  14. Auleley GR, Giraudeau B, Dougados M, Ravaud P (2000) Radiographic assessment of hip osteoarthritis progression: impact of reading procedures for longidudinal studies. Ann Rheum Dis 59:422–427

    Article  PubMed  CAS  Google Scholar 

  15. Bingham CO, Buckland-Wright C, Garnero P et al (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee. Arthritis Rheum 54:3494–3507

    Article  PubMed  CAS  Google Scholar 

  16. Spector TD, Conaghan PG, Buckland-Wright C et al (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res and Therap 7:R625–R633

    Article  CAS  Google Scholar 

  17. Buckland-Wright JC, Messent EA, Bingham CO, Ward RJ, Tonkin W (2007) A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthitic knee patients. Rheumatology 46:257–264

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

Ch. Roux received research grants and or honoraria from Servier, Novartis, Amgen, MSD, Roche, Lilly. P. Richette has received honorarium from Servier, Artialis, Novartis, Sanofi, Pfizer, Expanscience, Genevrier, Ipsen, Menarini, Abbot, MSD.

Author information

Authors and Affiliations

  1. Assistance-Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Rhumatologie, Université Paris Descartes, 75014, Paris, France

    C. Roux

  2. Assistance-Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Université Paris Diderot, 75010, Paris, France

    P. Richette

  3. Service de Rhumatologie, Hôpital Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France

    C. Roux

Authors
  1. C. Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Richette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Roux.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roux, C., Richette, P. Impact of treatments for osteoporosis on osteoarthritis progression. Osteoporos Int 23 (Suppl 8), 881–883 (2012). https://doi.org/10.1007/s00198-012-2168-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-2168-6

Keywords

Search

Navigation